Blanken, Maarten <br/><br/>
Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks.  [electronic resource] 

 -  Contemporary clinical trials  Nov 2012 
 - 1287-92 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1559-2030 
<br/><br/><label>Standard No.: </label>10.1016/j.cct.2012.07.010  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antiviral Agents--administration & dosage<br/>Double-Blind Method<br/>Ethics, Research<br/>Female<br/>Gestational Age<br/>Humans<br/>Infant<br/>Infant, Newborn<br/>Male<br/>Palivizumab<br/>Recurrence<br/>Respiratory Sounds--drug effects<br/>Respiratory Syncytial Virus Infections--complications